FEDERAL COURT OF AUSTRALIA
Interpharma Pty Ltd v Commissioner of Patents [2008] FCA 1498
PATENT – Infringement – Pharmaceutical compound – No claim for particular stereochemistry – Whether racemate only claimed – Whether claims covered β anomer.
PATENT – Validity – Pharmaceutical compound – Utility – Whether invention useful according to promises in patent – Whether toxicity compromises utility.
PATENT – Infringement – Process for manufacture of chemical compound.
PATENT – Validity – Process for manufacture of chemical compound – Whether invention lacked inventive step – Common general knowledge – Whether lack of inventive step established an interlocutory application.
INTERLOCUTORY INJUNCTION – Alleged infringement of patent – Whether prima facie case made out – Whether defences of invalidity made out – Necessary strength of defences on interlocutory application – Whether damages an adequate remedy – Balance of convenience – Alleged infringer entering established market – Whether possible to restore applicant to present position – Relevance of apparent strength of substantive cases.
Patents Act 1990 (Cth) ss 18(1)(b), 18(1)(c), 78
AB Hassle v Pharmacia (Australia) Pty Ltd (1995) 33 IPR 63
Aktiebolaget Hassle and Anor v Alphapharm Pty Ltd (2002) 212 CLR 411
Alphapharm Pty Ltd v H Lundbeck A/S [2008] FCA 559
Apotex Pty Ltd v Sanofi-Aventis [2008] FCA 194Australian Broadcasting Corporation v O’Neill (2006) 227 CLR 57
Beecham Group Ltd v Bristol Laboratories Pty Ltd (1968) 118 CLR 618
Castlemaine Tooheys Ltd v South Australia (1986) 161 CLR 148
Hexal Australia Pty Ltd v Roche Therapeutics Inc (2005) 66 IPR 325
Interpharma Pty Ltd v Commissioner of Patents [2008] FCA 1283
Merck & Co Inc v GenRx Pty Ltd (2006) 70 IPR 286Minnesota Mining & Manufacturing Co v Tyco Electronics Pty Ltd (2002) 56 IPR 248
Pharmacia Italia SpA v Interpharma Pty Ltd (2005) 67 IPR 397
Plimpton v Spiller (1876) 4 Ch D 286
Ranbaxy Australia Pty Ltd v Warner-Lambert Company LLC [2008] FCAFC 82
Tidy Tea Ltd v Unilever Australia Ltd (1995) 32 IPR 405INTERPHARMA PTY LTD v THE COMMISSIONER OF PATENTS; ELI LILLY & COMPANY and ELI LILLY AUSTRALIA PTY LTD; INTERPHARMA PTY LTD
VID 160 of 2008
JESSUP J
10 OCTOBER 2008
MELBOURNE
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
VID 160 of 2008
BETWEEN:
INTERPHARMA PTY LTD
ApplicantELI LILLY & COMPANY
First Cross-ClaimantELI LILLY AUSTRALIA PTY LTD
Second Cross-ClaimantAND:
THE COMMISSIONER OF PATENTS
RespondentINTERPHARMA PTY LTD
Cross-Respondent
JUDGE:
JESSUP J
DATE OF ORDER:
10 OCTOBER 2008
WHERE MADE:
MELBOURNE
UPON the cross-claimants by their counsel undertaking:
(a)to submit to such order (if any) as the court may consider to be just for the payment of compensation, to be assessed by the court or as it may direct, to any person, whether or not a party, adversely affected by the operation of the interlocutory order or undertaking or any continuation (with or without variation) thereof; and
(b)to pay the compensation referred to in (a) to the person…
Keep reading for free
Create a free CaseChat account to read Interpharma Pty Ltd v Commissioner of Patents and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2008] FCA 1498
- Decision Date
CaseChat Overview and Summary
The primary legal issues before the court were whether Health Care Direct's production and distribution of EBEGEMCIT infringed on Interpharma's patents and whether an interlocutory injunction should be granted to restrain Health Care Direct from marketing the product. The court had to consider the validity of Interpharma's patents, the nature of the alleged infringement, and the potential impact of the injunction on Health Care Direct's operations and the PBS listing process. The court also needed to balance the urgency of the situation with the need for a fair hearing of the merits of the case.
In its decision, the court found that Interpharma had established a serious question to be tried regarding the validity of the patents in question. The court concluded that the cross-claimant had made out a prima facie case of patent infringement and that an interlocutory injunction was warranted. The court emphasised the need for Health Care Direct to withdraw its application for the inclusion of EBEGEMCIT in the PBS to avoid any practical effect, given the administrative timeline for PBS updates. The court granted the relief sought by Interpharma, including an injunction against the marketing of EBEGEMCIT and a requirement for Health Care Direct to withdraw its PBS application. The court also set out a detailed timetable for the discovery process and the trial, reserving costs for later determination.
The court's final orders included restraining Health Care Direct from marketing and distributing EBEGEMCIT, requiring the withdrawal of the PBS application, and establishing a timeline for document discovery and trial preparation. The court mandated specific dates for the filing and serving of documents and affidavits, and set a trial date for June 2009, with an estimated duration of 10 days. The parties were granted liberty to apply for further orders as necessary.
Orders
Orders of the court
1. The cross-respondent, whether by its servants, agents or otherwise, be restrained until the hearing and determination of this proceeding or further order from making, importing, selling, offering to sell, otherwise disposing of, offering otherwise to dispose of or keeping for any of those purposes, the following pharmaceutical formulations;
(a) EBEGEMCIT gemcitabine 200mg (as hydrochloride) powder for injection vial having ARTG Number 129350; and
(b) EBEGEMCIT gemcitabine 1g (as hydrochloride) powder for injection vial having ARTG Number 129351.
2. The cross-respondent, whether by its servants, agents or otherwise, be restrained until the hearing and determination of this proceeding or further order from making, importing, selling, offering to sell, otherwise disposing of, offering otherwise to dispose of or keeping for any of those purposes, any gemcitabine hydrochloride formulation wherein the active pharmaceutical ingredient was (or will be) manufactured by ScinoPharm Taiwan Limited.
3. The cross-respondent, by 12 noon on Tuesday, 14 October 2008, take all steps as are necessary to withdraw its application for the inclusion of the EBEGEMCIT gemcitabine hydrochloride formulations referred to in paragraph 1 above on the Schedule of Pharmaceutical Benefits and serve on the Cross-Claimants an affidavit made by a proper officer of the Cross-Respondent’s identifying each of the steps that have been taken.
4. The cross-respondent, whether by its servants, agents or otherwise, be restrained until the hearing and determination of this proceeding or further order from making any application for the inclusion of a gemcitabine hydrochloride formulation on the Schedule of Pharmaceutical Benefits wherein the active pharmaceutical ingredient was (or will be) manufactured by ScinoPharm Taiwan Limited.
5. Costs be reserved.
6. All issues as to liability are to be heard prior to, and separately from, any issues as to quantum.
7. Each party file and serve on or before 24 October 2008 a list of categories of documents of which they seek discovery by the opposite party, such categories to be confined to those documents likely to be relevant and useful at the trial.
8. Each party to make discovery of the categories of documents sought by the opposing party on or before 28 November 20087.
9. Each of the parties to file and serve on or before 16 January 2009 any affidavits upon which they intend to rely in chief at the trial of this proceeding.
10. Each of the parties to file and serve on or before 27 March 2009 any affidavits on which they intend to rely in answer at the trial of this proceeding.
11. Each of the parties to file and serve on or before 1 May 2009 any affidavits in reply upon which they intend to rely at the trial of this proceeding.
12. The trial of this proceeding to be fixed for hearing on the first available date on or after 1 June 2009 with an estimate of 10 days.
13. Each party have liberty to apply on 3 days’ written notice.
Background
Background to the litigation
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Established by: JESSUP J
Full text does not contain this section.